Could differential censoring explain the inconsistent results in phase 3 trials investigating the addition of PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors to platinum-based chemotherapy as first-line treatment in advanced urothelial carcinoma? The gene discussed is PDCD1; the disease is urothelial carcinoma.